Drugs / BSF 208075
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00046319 | Sep 2002 → Jun 2003 | pulmonary hypertension | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BSF 208075 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00046319 ↗ |
| Route | Oral | “10.0 mg po qd” NCT00046319 ↗ |